Catalent Inc Stock News

Catalent's (CTLT) deal with Elliott and earnings report boost its shares. The company will likely improve its value and growth with the agreement and its strategic investments.

The contract drug manufacturer posted steep declines in key fundamentals in its fiscal fourth quarter. Still, it booked more revenue than analysts expected; guidance also topped expectations.

Catalent, Inc. (NYSE:CTLT ) Q4 2023 Earnings Conference Call August 29, 2023 8:15 AM ET Company Participants Paul Surdez - Vice President, Investor Relations John Greisch - Executive Chair, Board Ales

Catalent (CTLT) records lower revenues in Biologics segment in its fourth-quarter fiscal 2023, resulting in overall soft preliminary performance.

Catalent (CTLT) shares surged more than 5% in early trading on Tuesday after the struggling drugmaker secured a deal with activist investor Elliott Investment Management.

Catalent Inc is close to a settlement deal with activist investor Elliott Investment Management, which will include the appointment new directors and a pledge to review strategic alternatives such as

Catalent (NYSE: CTLT ) stock is getting a boost on Tuesday after the consumer health company reached an agreement with Elliott Investment Management. This has Catalent adding four new directors to its

Catalent (CTLT) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $1.19 per share a year ago.

Shares of Catalent Inc. CTLT, +1.67% jumped 4.1% in premarket trading Tuesday, after the maker of products used by drug makers and consumer health companies announced an cooperation agreement with act

Catalent Inc is close to reaching a settlement with Elliott Investment Management that would lead to a shake-up of the U.S. contract drug manufacturer's board of directors after its share price lost h

Catalent's plant in Bloomington, Indiana, will fill injection pens for Novo Nordisk's weight-loss drug Wegovy as part of the two companies' expanded supply agreement, two sources familiar with the mat

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it will release financ

Equities have pulled back from their late July highs, though the Q2 reporting season has been solid. We spot three firms with unusual corporate event activity. A problem child is back at the top of ou

Morgan Stanley on Friday lifted its forecast for annual sales of weight-loss drugs to $77 billion, as patient demand for the medicines has outstripped supply and been fueled by a social-media frenzy.

Catalent Inc (NYSE: CTLT) jumped nearly 10% this morning after Elliott Investment Management was reported to have built a sizable stake in the contract drug manufacturer.